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Abstract
We assessed CD4 count at initial presentation for HIV care among ≥50-year-olds from 1997-2007 in 13 US and
Canadian clinical cohorts and compared to <50-year-olds. 44,491 HIV-infected individuals in the North American
AIDS Cohort Collaboration on Research and Design (NA-ACCORD) were included in our study. Trends in mean CD4
count (measured as cells/mm3) and 95% confidence intervals ([,]) were determined using linear regression stratified
by age category and adjusted for gender, race/ethnicity, HIV transmission risk and cohort. From 1997-2007, the pro-
portion of individuals presenting for HIV care who were ≥50-years-old increased from 17% to 27% (p-value < 0.01).
The median CD4 count among ≥50 year-olds was consistently lower than younger adults. The interaction of age
group and calendar year was significant (p-value <0.01) with both age groups experiencing modest annual
improvements over time (< 50-year-olds: 5[4 , 6] cells/mm3; ≥50-year-olds: 7[5 , 9] cells/mm3), after adjusting for
sex, race/ethnicity, HIV transmission risk group and cohort; however, increases in the two groups were similar after
2000. A greater proportion of older individuals had an AIDS-defining diagnosis at, or within three months prior to,
first presentation for HIV care compared to younger individuals (13% vs. 10%, respectively). Due to the increasing
proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presenta-
tion for HIV care, renewed HIV testing efforts are needed.
Findings
We recently reported that the median CD4 count at first
presentation for HIV care in the US and Canada
increased from 256 (IQR: 96-455) to 317 (IQR: 135-517)
from 1997 to 2007, yet remained below 350 cells/mm3 -
the current cut-off for initiating highly active antiretro-
viral therapy (HAART) [1,2]. Over the study period,
there was an increase in the median age at first presen-
tation for HIV care (from 40 to 43 years in 1997 to
2007, p < 0.01) [1]. According to the Centers for Disease
Control and Prevention (CDC) 10% of the total incident
HIV infections occurring in the US in 2006 were among
adults ≥50-years-old [3]. Further, the prevalence of HIV
infection in individuals ≥50 years of age is rapidly
increasing [4,5], yet there is evidence that this older age
group may not be as aware of HIV infection and the
need for preventive measures and less likely to be tested
and seek care early [6-9]. As this is the largest cohort
collaboration of HIV-infected individuals in North
America, we have conducted a new analysis that focuses
on CD4 at first presentation for HIV care among
patients ≥50-years-old.
We briefly describe study population and analytical
methods; more details are provided in Althoff et al. [1].
All patients were enrollees in clinical care cohorts con-
tributing to the North American Cohort Collaboration
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on Research and Design (NA-ACCORD) [10], a regional
group of the International Epidemiological Databases to
Evaluate AIDS (IeDEA) project. Each cohort’s participa-
tion in NA-ACCORD was approved by the respective
local institutional review boards. All 14 NA-ACCORD
clinical cohorts agreed to participate in this study
although one was excluded because their study popula-
tion enrollment criteria restricted to those in later stages
of HIV disease. These 13 clinical cohorts have clinical
sites in 17 US states, Washington DC, and 3 Canadian
provinces. Our primary focus was on HIV-infected adults
who were ≥50 years of age and who first presented for
clinical care between January 1997 and December 2007,
as compared to individuals presenting at younger ages.
First presentation for HIV clinical care was defined as the
date (month and year) at which the first CD4 count was
reported.
The first measured CD4 was our outcome of interest.
The month and year in which the CD4 was measured
were recorded. If there was more than one CD4 mea-
surement in the first month at presentation for HIV
care, we calculated the mean CD4 count for the month.
Other information obtained at first presentation for care
included self-reported year of birth, gender, race/ethni-
city (as black, white, Latino and other/unknown) and
HIV transmission risk group (male-to-male sex (MSM),
injection drug use (IDU) including MSM/IDU, hetero-
sexual contact and other/unknown).
Statistical comparisons of demographic and clinical
characteristics across calendar dates were made using
the Cochran-Armitage trend test for categorical vari-
ables or the Cuzick trend test for continuous variables.
We determined the median absolute CD4 count and
interquartile range (IQR) at first presentation for HIV
clinical care annually from 1997 through 2007, by age
group. Multivariate linear regression models were used
to describe the annual trends in estimated mean CD4
count using a linear variable for year, stratified by age
group and adjusting for cohort demographic and risk
characteristics; 95% confidence intervals ([,]) were also
estimated using these models. Sensitivity analyses were
conducted by omitting participants from the Veterans
Aging Cohort Study (VACS) and the HIV Research Net-
work (HIVRN) as these two cohorts contribute ≈50% of
the participants in the NA-ACCORD and the median
age in the VACS was slightly older. Results with a two-
sided p-value of <0.05 were considered statistically sig-
nificant. Analyses were conducted using SAS, version 9.
After excluded individuals contributing data during
the first year that the cohort contributed data to the
NA-ACCORD to remove individuals who may have
been previously in care, a total of 67,961 adults received
HIV clinical care at one of the participating NA-
ACCORD sites between 1997 and 2007 and had
complete date and CD4 measurement information. Of
these, 21,983 (32%) had a prior history of antiretroviral
therapy or HIV-1 RNA results and 1,487 (2%) had an
AIDS-defining diagnosis recorded more than 3 months
prior to the first recorded CD4 count. These individuals
were excluded as they were likely to have been pre-
viously in care. Our study population consisted of
44,491 HIV-infected individuals.
The proportions of individuals who were < and ≥50-
years-old who first presented for HIV care each year are
shown in Table 1; additional characteristics of the study
population can be found in Althoff et al. [1]. From
1997-2007, the proportion of individuals presenting for
HIV care who were aged ≥50 years increased from 17%
to 27% (p-value < 0.01). The increase over time in med-
ian CD4 count at first presentation for care was similar
in absolute magnitude in both age groups (67 cells/mm3
and 63 cells/mm3 from 1997 to 2007 among <50-year-
olds and ≥50-year-olds, respectively). However, the ≥50-
year-olds had a median CD4 count of 266 cells/mm3,
compared to 336 cells/mm3 among <50-year-olds, in
2007.
The median CD4 count was consistently lower in the
≥50-year-olds compared to the <50-year-olds from 1997
to 2007 (Figure 1). The proportion of individuals at first
presentation for HIV care who had a CD4 count ≥350
cells/mm3 was lower in the ≥50-year-olds compared to
the <50-year-olds; this proportion increased over time
for both age groups.
In the multivariate analyses, the estimated annual
change in CD4 count from 1997 to 2007 was higher
among ≥50-year-olds years (7 [5 , 9] cells/mm 3) com-
pared to <50-year-olds (5 [4 , 6] cells/mm3) adjusting
for sex, race and ethnicity, HIV transmission risk group
and cohort. Findings were similar in sensitivity analyses.
The interaction of age group and calendar year was sta-
tistically significant (p-value <0.01). After restriction to
the years 2000-2007 in the ≥50-year-olds, the estimated
annual change in CD4 count was 4 [1, 7] cells/mm3,
similar to the change in the <50-year-olds from
1997-2007 (5 [4, 6]cells/mm3).
Overall, the proportion of individuals who had an
AIDS-defining diagnosis recorded at, or 3 months prior
to, the first CD4 measurement was highest among those
aged ≥50 years (< 50-year-olds: 10%; ≥50-year-olds: 13%;
p-value < 0.01); in sensitivity analyses, these proportions
increased (< 50-year-olds: 12%; ≥50-year-olds: 18%;
p-value < 0.01). The proportions who had an AIDS-
defining diagnosis at first presentation for care
decreased from 1997 to 2007 in both age groups
(Table 1). Older individuals had a greater proportion
with an AIDS-defining diagnosis in all years, however
this disparity decreased over time (Table 1); in sensitiv-
ity analyses the decreases were of less magnitude
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Table 1 Characteristics of N = 44,491 participating patients, by year at first presentation
Total 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 p-value‡
N = 44,491 N = 4,479 N = 4,412 N = 4,857 N = 5,262 N = 4,258 N = 4,063 N = 3,688 N = 3,773 N = 3,486 N = 3,354 N = 2,859
Age (years)
18-< 50 35,093 79% 3,698 83% 3,624 82% 3,953 81% 4,244 81% 3,344 79% 3,158 78% 2,855 77% 2,912 77% 2,709 78% 2,516 75% 2,080 73% < 0.01
≥50 9,398 21% 781 17% 788 18% 904 19% 1,018 19% 914 21% 905 22% 833 23% 861 23% 777 22% 838 25% 779 27% < 0.01
AIDS-defining illness
18-< 50 3,390 10% 417 11% 385 11% 362 9% 370 9% 344 10% 331 10% 277 10% 270 9% 251 9% 208 8% 175 8% < 0.01
≥50 1,242 13% 142 18% 127 16% 119 13% 121 12% 133 15% 119 13% 105 13% 105 12% 102 13% 95 11% 74 9% < 0.01
CD4+ T-cell Count (cells/mm3)
18-< 50
Median 298 269 277 275 284 293 313 296 312 323 333 336 < 0.01
IQR 112-493 100-467 96-481 99-464 104-494 100-494 124-501 114-504 127-499 134-500 141-512 152-522
≥50
Median 251 203 211 246 261 234 272 274 261 272 273 266 < 0.01
IQR 90-457 80-390 65-403 88-440 102-464 88-443 111-457 92-475 83-487 81-511 107-491 111-494
‡P-values calculated using Cochran-Armitage test for categorical variables or Cuzick’s test for continuous variables.
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(≥50-year-olds: 20% in 1997 to 15% in 2007, p-value <
0.01; <50-year-olds: 13% in 1997 to 12% in 2007, p-
value < 0.01). Finally, among individuals who had an
AIDS-defining diagnosis at first presentation for care,
the proportion of older individuals who had ≥2 AIDS-
defining diagnosis was similar to that of younger indivi-
duals (18% vs. 19%, p = 0.19).
Our study has three important findings: 1) the propor-
tion of individuals at first presentation for care who are
aged ≥50 years has increased over the past 11 years; 2)
older individuals at first presentation of care consistently
had a lower median CD4 count compared to younger
individuals; and 3) a greater proportion of older indivi-
duals have an AIDS-defining diagnosis at, or within
three months prior to, first presentation for HIV care
compared to younger individuals.
The increase in the proportion of individuals who
were ≥50 years at first presentation for care has implica-
tions for effective HIV management and survival for
older infected individuals. Older individuals initiating
HAART have a decreased immune response [11-18] and
mortality increases with lower CD4 counts at HAART
initiation [19]. In addition, older individuals at first pre-
sentation for care may have existing co-morbid condi-
tions that may complicate HIV treatment decisions.
From a public health perspective, a delay in presentation
for treatment increases the risk for ongoing transmission
[20-23]. These data suggest improved screening by
health providers may help detect HIV infection earlier
and at younger ages.
The estimated mean annual increase in CD4 count for
individuals aged < and ≥50 years is small and likely of
little clinical relevance as the within-patient variation in
CD4 counts is ~25%. More importantly, the annual
median CD4 count is still well below the CD4 recom-
mended for initiation of HAART [24]. The proportion
of individuals presenting with a CD4 ≥350 cell/smm3
increased in all age groups, however, the proportion was
approximately 10% lower among ≥50-year-olds. This
suggests the potential for greater HIV treatment initia-
tion guideline adherence if effective testing and treat-
ment interventions target older individuals.
Finally, our data suggest older individuals are entering
into care with advanced HIV disease. The CDC recently
reported an increase in the proportion of ≥50-year-olds
in the US who had a first HIV diagnosis within a year
before AIDS diagnosis compared to 30-< 50-year-olds
[25]; the Public Health Agency of Canada has noted the
increase among ≥50 year-olds [26,27]. Data from New
York City showed the proportion of new HIV diagnoses
that are concurrent with an AIDS diagnoses increased
with older age [28].
There are limitations to our study, including our lack
of data regarding time since seroconversion. We chose
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Figure 1 Median CD4 count, and the proportion of individuals who have a CD4 count ≥350 cells/mm3, at first presentation for HIV
clinical care.
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to stratify the data using a cut-off of 50 years. Although
there were more than enough individuals for additional
stratification at younger ages, additional stratification at
older ages was not possible.
While all age groups are experiencing modest
improvements in CD4 count at presentation over time,
older individuals have not “caught up.” These data sug-
gest that targeted renewed prevention and testing strate-
gies are needed in all age groups, including those ≥50-
years-old.
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